GlassScriptPhysician profile
Christopher M Milford
NPI 1801843396
$8,930.19
in general payments reported to CMS, 2019-2025
47 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $336 · 2021: $346 · 2022: $1,612 · 2023: $3,378 · 2024: $1,582 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,809 · Debt Forgiveness: $1,507 · Education: $111 · Honoraria: $4.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,808.86 |
| Debt Forgiveness | $1,506.90 |
| Education | $111.00 |
| Honoraria | $4.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cadwell Industries, INC | $1,506.90 | 2023 | |
| Abbvie INC. | $1,408.15 | 2021-2025 | |
| Biogen, INC. | $792.10 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $521.12 | 2022-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $379.63 | 2019-2025 | |
| Ucb, INC. | $356.50 | 2019-2025 | Briviact, Rystiggo |
| Genentech USA, INC. | $317.64 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Argenx US, INC. | $289.86 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $252.09 | 2022-2025 | Vyepti, Rexulti |
| Celgene Corporation | $251.50 | 2022-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $247.29 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $232.67 | 2021-2023 | |
| Amgen INC. | $196.03 | 2019-2024 | Uplizna |
| Genzyme Corporation | $190.85 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $163.54 | 2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Milford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.